TITLE:
Pretreatment Neutrophil/Lymphocytes Ratio in Non-Metastatic Colon Cancer as a Prognostic and Predictive Factor: A Retrospective Study
AUTHORS:
Manar Muhammed Muhammed, Ahmed Mustafa Elzawawy, Mohamed Abozeid, Sharehan Hassan Soliman
KEYWORDS:
Pretreatment Neutrophil/Lymphocytes Ratio-Non-Metastatic Cancer Colon
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.14 No.1,
January
12,
2023
ABSTRACT: Background: In
developed countries, colon cancer is the second most prevalent cancer, only exceeded by prostate cancer in
men and breast cancer in women. After Hepatocellular carcinoma, breast
cancer, bladder cancer, lung cancer, Non-Hodgkin Lymphoma and brain tumors,
colon cancer is the 7th most common cancer in Egypt, in both sexes,
representing 3.47% and 3%, in both male and female cancers, respectively. Aim of the Work: The aim of this study was to evaluate the prognostic and predictive
significance of pretreatment Neutrophil/lymphocytes ratio (NLR), in terms of
disease-free survival (DFS) and recurrence, in high-risk stage II and stage III
Colorectal cancer patients who underwent curative resection. Patients and Methods: We retrospectively evaluated 103
patients, who were submitted to upfront surgery as first therapeutic option in
curative intent, between January 2017 and December 2018. Pretreatment
Neutrophil/lymphocytes ratio (NLR), as well as demographics, clinical,
histopathologic, and laboratory data were analyzed. Univariate and multivariate
analyses were conducted to identify prognostic factors associated with disease
free survival (DFS) and recurrence. Results: The cutoff point of Neutrophils/lymphocytes ratio (NLR) was calculated with
Kaplan-Meier curves and log-rank test to 3. This study revealed that
neutrophils/lymphocytes ratio (NLR) was significantly associated with disease
free survival (p as no
difference in efficacy between both chemotherapy regimens FOLFOX and XELOX in
both high-risk stage II and stage III colon cancer regarding disease free
survival & the toxicity profile associated with each regimen and its grades
between patients. Conclusion: Our
study suggests that preoperative Neutrophils/lymphocytes ratio (NLR) more than 3 may be an independent prognostic marker for
TTR (time to recurrence) in high-risk stage II and stage III colon
cancer patients.